1-3 of 3
Kiyohide Fujimoto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ALKBH3 Contributes to Survival and Angiogenesis of Human Urothelial Carcinoma Cells through NADPH Oxidase and Tweak/Fn14/VEGF Signals

Keiji Shimada, Tomomi Fujii, Kazutake Tsujikawa, Satoshi Anai, Kiyohide Fujimoto, Noboru Konishi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5247–5255.
https://doi.org/10.1158/1078-0432.CCR-12-0955
Published: 30 September 2012
View article titled, ALKBH3 Contributes to Survival and Angiogenesis of Human Urothelial Carcinoma Cells through NADPH Oxidase and Tweak/Fn14/VEGF Signals
Open the PDF for ALKBH3 Contributes to Survival and Angiogenesis of Human Urothelial Carcinoma Cells through NADPH Oxidase and Tweak/Fn14/VEGF Signals in another window
Includes: Supplementary data
Journal Articles

Function of JunB in Transient Amplifying Cell Senescence and Progression of Human Prostate Cancer

Noboru Konishi, Keiji Shimada, Mitsutoshi Nakamura, Eiwa Ishida, Ichiro Ota, Nobumichi Tanaka, Kiyohide Fujimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4408–4416.
https://doi.org/10.1158/1078-0432.CCR-07-4120
Published: 15 July 2008
View article titled, Function of JunB in Transient Amplifying Cell Senescence and Progression of Human Prostate Cancer
Open the PDF for Function of JunB in Transient Amplifying Cell Senescence and Progression of Human Prostate Cancer in another window
Journal Articles

A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma

Hirotsugu Uemura, Kiyohide Fujimoto, Motoyoshi Tanaka, Motoyoshi Yoshikawa, Yoshihiko Hirao, Shigeya Uejima, Kazuhiro Yoshikawa, Kyogo Itoh
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (6): 1768–1775.
https://doi.org/10.1158/1078-0432.CCR-05-2253
Published: 21 March 2006
View article titled, A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma
Open the PDF for A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma in another window